The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...

TECHNOLOGY: Activation assays A method for engineering protease-inducible Cas9 proteins could be used to screen for protease-activating drug compounds. Generation of a protease-inducible Cas9 (ProCas9) involves two steps: inactivating Cas9 by circular permutation, a process...

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV Membrane-bound transcription factor peptidase site-1 (MBTPS1; SKI-1) Cell culture studies suggest inhibiting SKI-1 could help treat HCV infection. In cultured hepatocytes, a small...

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML), leukemia Sphingosine kinase 1 (SphK1) Studies in cancer cells and in mice suggest that inhibitors specific...

A paper published in Blood suggests that going upstream of the known cancer target sphingosine 1-phosphate could be a better approach than hitting site-1 protease ( S1P ) itself. By specifically hitting one of the two sphingosine...

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis. 1 The...